Recent Updates
Recently added Catalysts

MK0803, lovastatin

Phase 3

Hypercholesterolemia | Small molecule | Metabolic |Merck & Company, Inc.|Last Updated: Oct 2, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment1,000
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00092846A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)PHASE3 COMPLETED 1,000Dec 4, 2002 -Oct 2, 2017 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of patients who make appropriate decision for self-management.
Secondary Endpoints
Percentage of patients who make appropriate decision to discontinue therapy or consult with a physician; the incidence of adverse experiences.
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposePREVENTION
Interventions
NameTypeDescription
MK0803, lovastatinDRUG -
Self-Management SystemBEHAVIORAL -
Unlock Study Design Details
Eligibility Criteria
Age Range45 Years — N/A
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Must be able to read and understand English without assistance. * For Males: Minimum age 45 years and Maximum age N/A (No limit). * For Females: Minimum age 55 years and Maximum age N/A (No limit). Exclusion Criteria: * Pregnant or nursing * Drug allergy

Unlock Eligibility Criteria